Auxilius

Name: Auxilius
Brand: Auxilius

AI Native

Clinical Trial Financial Management Software for Biopharma

Est 2020|Valuation $57M|Raised $23.4M|15 Ref Customers

LinkedIn 16K|Website|Web traffic 5K|FTEs 49|HQ New York, New York, US

MarketsAccount Reconciliation Budgeting & Forecasting

01Competitive Landscape

Narrative analysis

- Medidata Grants Manager is positioned within a larger clinical platform and focuses on grants lifecycle functionality; organizations already standardized on that platform may find tighter integration within the existing ecosystem. - Greenphire focuses on payments execution and related operational workflows; organizations primarily seeking payments infrastructure may prefer that solution. - Auxilius frames itself as an intermediary layer addressing close, accrual, and audit artifacts by linking clinical activity to finance processes. The benefit for a given buyer depends on existing tooling and the degree of clinical/finance fragmentation.

Adoption / market traction signals

Press coverage and vendor communications indicate pilot programs and early adoption activity reported in media and vendor materials, including vendor-reported pilot activity and program spend metrics. Vendor-published messaging later cites an increased customer base and revenue growth; those claims were not independently verified in this research.

	Auxilius	Medidata Rave Grants Manager	Greenphire (participant/site payments)
Starting Price	Not publicly listed (demo-led)	Not publicly listed (enterprise sales)	Not publicly listed (enterprise sales)
Primary focus	Accrual/close/forecast automation tied to clinical drivers; audit documentation	Investigator grant lifecycle management within a clinical-platform ecosystem	Participant and site payments infrastructure and payment execution
Key strength (relative)	Linking clinical drivers to finance workflows and providing audit-focused artifacts (per vendor)	Integration with a broader clinical operations product suite	Payments specialization and established payment workflows and networks
Key weakness (relative)	Limited independent public reviews; pricing opacity; value dependent on integrations/data mapping	May not cover full accrual/forecast close workflows outside grants lifecycle	May not provide full accrual/forecast close functionality

01Competitive Landscape

Narrative analysis

Medidata Grants Manager is positioned within a larger clinical platform and focuses on grants lifecycle functionality; organizations already standardized on that platform may find tighter integration within the existing ecosystem.
Greenphire focuses on payments execution and related operational workflows; organizations primarily seeking payments infrastructure may prefer that solution.
Auxilius frames itself as an intermediary layer addressing close, accrual, and audit artifacts by linking clinical activity to finance processes. The benefit for a given buyer depends on existing tooling and the degree of clinical/finance fragmentation.

Adoption / market traction signals

Press coverage and vendor communications indicate pilot programs and early adoption activity reported in media and vendor materials, including vendor-reported pilot activity and program spend metrics. Vendor-published messaging later cites an increased customer base and revenue growth; those claims were not independently verified in this research.

	Auxilius	Medidata Rave Grants Manager	Greenphire (participant/site payments)
Starting Price	Not publicly listed (demo-led)	Not publicly listed (enterprise sales)	Not publicly listed (enterprise sales)
Primary focus	Accrual/close/forecast automation tied to clinical drivers; audit documentation	Investigator grant lifecycle management within a clinical-platform ecosystem	Participant and site payments infrastructure and payment execution
Key strength (relative)	Linking clinical drivers to finance workflows and providing audit-focused artifacts (per vendor)	Integration with a broader clinical operations product suite	Payments specialization and established payment workflows and networks
Key weakness (relative)	Limited independent public reviews; pricing opacity; value dependent on integrations/data mapping	May not cover full accrual/forecast close workflows outside grants lifecycle	May not provide full accrual/forecast close functionality